Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime.

Abstract

This article reviews the new beta-lactam (beta-lactam) antibiotics doripenem, ceftobiprole, and ceftaroline. It covers pharmacokinetic and pharmacodynamic properties, dosing, in vitro activities, safety, and clinical trial results. Doripenem (Doribax) has been approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal and urinary tract infections. At this writing, ceftobiprole is under review by the FDA for approval based on results of phase 3 clinical trials, whereas at least one phase 3 clinical trial of ceftaroline has been completed. The article also reviews recent data suggesting increased overall mortality with Cefepime (Maxipime) use compared with other beta-lactam antibiotics and the potential risk for neurotoxicity in the setting of renal failure.

• Authors: Jose A Bazan, Stanley I Martin, Kenneth M Kaye
• Journal: Infectious disease clinics of North America (Infect Dis Clin North Am) Vol. 23 Issue 4 Pg. 983-96, ix (Dec 2009) ISSN: 1557-9824 [Electronic] United States
• PMID: 19909894 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• beta-Lactams

Topics

• Anti-Bacterial Agents (pharmacokinetics, pharmacology, therapeutic use)
• Bacteria (drug effects)
• Bacterial Infections (drug therapy)
• Humans
• beta-Lactams (pharmacokinetics, pharmacology, therapeutic use)